News Quantified

BBIO – bridgebio pharma, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

What Recent Clinical Wins Mean For BridgeBio Pharma's Evolving Growth Story [Yahoo! Finance]

BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating on the stock.

BridgeBio to Participate in December Investor Conferences

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $76.00 to $84.00. They now have an "overweight" rating on the stock.

-4.9%

MISS

-8.9%

MISS

5.3%

BEAT

Sanford C. Bernstein

Form 4 BridgeBio Pharma, Inc. For: Dec 08 Filed by: Apuli Maricel

Form 4 BridgeBio Pharma, Inc. For: Dec 04 Filed by: Kumar Neil

Form 4 BridgeBio Pharma, Inc. For: Nov 20 Filed by: Kumar Neil

Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil

Form 4 BridgeBio Pharma, Inc. For: Nov 17 Filed by: Lo Andrew

Top News Gainers

3/19 BridgeBio Pharma (NASDAQ: BBIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 26.9%

12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%

4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%

10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%

11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%

7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%

4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%

12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%

12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%

11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%

Top News Decliners

3/12 BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations -16.6%

12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%

6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%

2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%

9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%

1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%

4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%

12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%

12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%

3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day